Kristen Nadeau
Concepts (548)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Resistance | 78 | 2026 | 1244 | 10.530 |
Why?
| | Diabetes Mellitus, Type 2 | 92 | 2026 | 2602 | 9.390 |
Why?
| | Diabetes Mellitus, Type 1 | 58 | 2026 | 3937 | 5.230 |
Why?
| | Pediatric Obesity | 28 | 2026 | 638 | 4.480 |
Why?
| | Metformin | 22 | 2024 | 329 | 4.130 |
Why?
| | Blood Glucose | 62 | 2026 | 2344 | 3.970 |
Why?
| | Obesity | 38 | 2025 | 3118 | 3.460 |
Why?
| | Diabetic Nephropathies | 17 | 2026 | 322 | 3.420 |
Why?
| | Adolescent | 179 | 2026 | 22573 | 3.380 |
Why?
| | Polycystic Ovary Syndrome | 15 | 2022 | 188 | 3.080 |
Why?
| | Hypoglycemic Agents | 27 | 2026 | 1399 | 3.070 |
Why?
| | Insulin | 32 | 2026 | 2516 | 2.160 |
Why?
| | Cardiovascular Diseases | 26 | 2026 | 2191 | 2.120 |
Why?
| | Prediabetic State | 13 | 2023 | 250 | 2.090 |
Why?
| | Child | 109 | 2026 | 22739 | 2.050 |
Why?
| | Glucose Tolerance Test | 26 | 2023 | 361 | 1.940 |
Why?
| | Hyperglycemia | 6 | 2022 | 379 | 1.900 |
Why?
| | Glucose Clamp Technique | 17 | 2021 | 199 | 1.840 |
Why?
| | Gastrectomy | 3 | 2026 | 166 | 1.820 |
Why?
| | Sleep | 14 | 2026 | 889 | 1.810 |
Why?
| | Fatty Liver | 9 | 2026 | 253 | 1.790 |
Why?
| | Mitochondria, Muscle | 7 | 2024 | 120 | 1.760 |
Why?
| | Obesity, Morbid | 7 | 2026 | 293 | 1.690 |
Why?
| | Puberty | 10 | 2026 | 137 | 1.670 |
Why?
| | Circadian Rhythm | 9 | 2025 | 513 | 1.620 |
Why?
| | Diabetes Mellitus | 8 | 2023 | 1101 | 1.620 |
Why?
| | Vascular Stiffness | 8 | 2024 | 487 | 1.520 |
Why?
| | Young Adult | 66 | 2025 | 14251 | 1.510 |
Why?
| | Humans | 209 | 2026 | 145763 | 1.480 |
Why?
| | Female | 151 | 2026 | 79035 | 1.470 |
Why?
| | Adipose Tissue | 7 | 2021 | 645 | 1.460 |
Why?
| | Body Mass Index | 31 | 2026 | 2447 | 1.440 |
Why?
| | Male | 132 | 2026 | 73003 | 1.360 |
Why?
| | Cystic Fibrosis | 9 | 2023 | 1163 | 1.360 |
Why?
| | Bariatric Surgery | 7 | 2026 | 253 | 1.360 |
Why?
| | Body Composition | 13 | 2026 | 693 | 1.310 |
Why?
| | Overweight | 6 | 2023 | 614 | 1.310 |
Why?
| | Insulin-Secreting Cells | 8 | 2021 | 392 | 1.290 |
Why?
| | Fructosamine | 4 | 2019 | 11 | 1.230 |
Why?
| | Exercise Tolerance | 5 | 2017 | 283 | 1.220 |
Why?
| | Fatty Acids, Nonesterified | 6 | 2018 | 154 | 1.210 |
Why?
| | Glucose Intolerance | 9 | 2022 | 142 | 1.160 |
Why?
| | Muscle, Skeletal | 11 | 2026 | 1791 | 1.160 |
Why?
| | Adiposity | 8 | 2025 | 532 | 1.160 |
Why?
| | Serum Albumin | 4 | 2019 | 147 | 1.150 |
Why?
| | Biomarkers | 24 | 2026 | 4302 | 1.100 |
Why?
| | Diabetic Cardiomyopathies | 3 | 2020 | 34 | 1.090 |
Why?
| | Deoxyglucose | 3 | 2019 | 51 | 1.060 |
Why?
| | Diabetes Complications | 5 | 2024 | 225 | 0.980 |
Why?
| | Glomerular Filtration Rate | 14 | 2024 | 765 | 0.980 |
Why?
| | Cross-Over Studies | 5 | 2026 | 610 | 0.980 |
Why?
| | Ventricular Function, Left | 3 | 2020 | 544 | 0.950 |
Why?
| | Triglycerides | 11 | 2022 | 520 | 0.940 |
Why?
| | Adiponectin | 4 | 2016 | 242 | 0.930 |
Why?
| | Diabetic Angiopathies | 7 | 2020 | 267 | 0.920 |
Why?
| | Age of Onset | 7 | 2025 | 557 | 0.910 |
Why?
| | Oxygen Consumption | 8 | 2024 | 719 | 0.900 |
Why?
| | Testosterone | 6 | 2024 | 416 | 0.900 |
Why?
| | Abdominal Fat | 1 | 2025 | 51 | 0.890 |
Why?
| | Leptin | 3 | 2023 | 248 | 0.880 |
Why?
| | Case-Control Studies | 19 | 2025 | 3634 | 0.850 |
Why?
| | Risk Factors | 33 | 2026 | 10917 | 0.820 |
Why?
| | Diabetes, Gestational | 4 | 2023 | 306 | 0.810 |
Why?
| | Sex Characteristics | 8 | 2025 | 789 | 0.800 |
Why?
| | Lipid Metabolism | 6 | 2020 | 529 | 0.770 |
Why?
| | Exercise | 15 | 2026 | 2205 | 0.770 |
Why?
| | Kidney | 11 | 2024 | 1496 | 0.760 |
Why?
| | Adult | 51 | 2025 | 40872 | 0.740 |
Why?
| | Actigraphy | 8 | 2026 | 148 | 0.730 |
Why?
| | Lipids | 7 | 2022 | 707 | 0.700 |
Why?
| | Heart | 1 | 2025 | 626 | 0.700 |
Why?
| | Metabolic Syndrome | 7 | 2020 | 361 | 0.690 |
Why?
| | Glycopeptides | 2 | 2021 | 45 | 0.690 |
Why?
| | Cross-Sectional Studies | 27 | 2025 | 5922 | 0.680 |
Why?
| | Lipolysis | 3 | 2018 | 44 | 0.680 |
Why?
| | Fatty Acids | 2 | 2019 | 457 | 0.660 |
Why?
| | Weight Reduction Programs | 2 | 2019 | 140 | 0.650 |
Why?
| | Hyperinsulinism | 2 | 2019 | 115 | 0.640 |
Why?
| | Fasting | 5 | 2022 | 279 | 0.640 |
Why?
| | Liver | 7 | 2025 | 1899 | 0.630 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2021 | 109 | 0.630 |
Why?
| | Double-Blind Method | 7 | 2024 | 2064 | 0.610 |
Why?
| | Monitoring, Physiologic | 1 | 2022 | 289 | 0.610 |
Why?
| | Obesity, Abdominal | 2 | 2024 | 47 | 0.610 |
Why?
| | Gastric Bypass | 1 | 2021 | 126 | 0.600 |
Why?
| | Inservice Training | 1 | 2020 | 118 | 0.590 |
Why?
| | Creatinine | 7 | 2022 | 515 | 0.590 |
Why?
| | Mass Screening | 7 | 2022 | 1361 | 0.590 |
Why?
| | Albuminuria | 5 | 2024 | 189 | 0.590 |
Why?
| | Uromodulin | 1 | 2019 | 22 | 0.580 |
Why?
| | Pulse Wave Analysis | 7 | 2023 | 267 | 0.580 |
Why?
| | Intra-Abdominal Fat | 4 | 2026 | 101 | 0.570 |
Why?
| | Aorta | 2 | 2019 | 440 | 0.570 |
Why?
| | Alaska Natives | 1 | 2020 | 97 | 0.570 |
Why?
| | Endocrinology | 1 | 2020 | 77 | 0.570 |
Why?
| | Myocardial Contraction | 1 | 2020 | 293 | 0.560 |
Why?
| | Oxidative Phosphorylation | 3 | 2018 | 209 | 0.550 |
Why?
| | Non-alcoholic Fatty Liver Disease | 5 | 2021 | 265 | 0.550 |
Why?
| | Cardiotonic Agents | 1 | 2018 | 94 | 0.550 |
Why?
| | Lipogenesis | 3 | 2019 | 62 | 0.540 |
Why?
| | Mentors | 1 | 2020 | 217 | 0.540 |
Why?
| | Interprofessional Relations | 1 | 2020 | 276 | 0.530 |
Why?
| | Absorptiometry, Photon | 6 | 2026 | 277 | 0.530 |
Why?
| | Glucose | 9 | 2023 | 1048 | 0.520 |
Why?
| | Magnetic Resonance Spectroscopy | 4 | 2024 | 627 | 0.520 |
Why?
| | Life Style | 6 | 2019 | 486 | 0.520 |
Why?
| | C-Peptide | 5 | 2026 | 190 | 0.510 |
Why?
| | Blood Vessels | 1 | 2018 | 167 | 0.510 |
Why?
| | Sleep Apnea, Obstructive | 4 | 2025 | 303 | 0.510 |
Why?
| | Mentoring | 1 | 2020 | 166 | 0.510 |
Why?
| | Sleep Deprivation | 3 | 2025 | 206 | 0.510 |
Why?
| | Respiratory Function Tests | 2 | 2020 | 544 | 0.500 |
Why?
| | Child Behavior | 1 | 2019 | 236 | 0.500 |
Why?
| | Peptide Fragments | 1 | 2021 | 696 | 0.500 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2020 | 394 | 0.490 |
Why?
| | Human Development | 1 | 2016 | 21 | 0.480 |
Why?
| | Hypoglycemia | 2 | 2023 | 480 | 0.480 |
Why?
| | Affect | 1 | 2019 | 321 | 0.480 |
Why?
| | Prognosis | 12 | 2025 | 4329 | 0.480 |
Why?
| | Echocardiography | 3 | 2020 | 648 | 0.470 |
Why?
| | Amino Acids | 2 | 2022 | 519 | 0.470 |
Why?
| | Sleep Wake Disorders | 2 | 2019 | 314 | 0.470 |
Why?
| | Lipoproteins | 2 | 2022 | 166 | 0.450 |
Why?
| | Schools | 1 | 2018 | 449 | 0.450 |
Why?
| | Thinness | 2 | 2013 | 100 | 0.450 |
Why?
| | Cardiorespiratory Fitness | 3 | 2024 | 74 | 0.440 |
Why?
| | Hyperandrogenism | 1 | 2015 | 25 | 0.430 |
Why?
| | Prevalence | 8 | 2025 | 2874 | 0.410 |
Why?
| | Indians, North American | 4 | 2023 | 598 | 0.400 |
Why?
| | Follow-Up Studies | 12 | 2025 | 5428 | 0.390 |
Why?
| | Cohort Studies | 14 | 2021 | 6032 | 0.390 |
Why?
| | Treatment Outcome | 12 | 2026 | 11793 | 0.390 |
Why?
| | Hemodynamics | 4 | 2022 | 1118 | 0.390 |
Why?
| | Cardiovascular System | 2 | 2012 | 139 | 0.380 |
Why?
| | Magnetic Resonance Imaging | 10 | 2026 | 3915 | 0.380 |
Why?
| | Glycation End Products, Advanced | 4 | 2019 | 81 | 0.380 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2026 | 149 | 0.380 |
Why?
| | Risk Reduction Behavior | 4 | 2023 | 217 | 0.360 |
Why?
| | Pediatrics | 2 | 2020 | 1125 | 0.350 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 3 | 2007 | 56 | 0.350 |
Why?
| | Comorbidity | 4 | 2025 | 1662 | 0.340 |
Why?
| | Islets of Langerhans | 2 | 2021 | 847 | 0.340 |
Why?
| | Alanine Transaminase | 3 | 2025 | 151 | 0.340 |
Why?
| | Lung Diseases | 1 | 2018 | 782 | 0.340 |
Why?
| | Uric Acid | 4 | 2021 | 167 | 0.330 |
Why?
| | Pilot Projects | 6 | 2024 | 1897 | 0.320 |
Why?
| | Sex Factors | 7 | 2025 | 2110 | 0.310 |
Why?
| | Hypogonadism | 1 | 2010 | 93 | 0.310 |
Why?
| | Prospective Studies | 8 | 2022 | 8075 | 0.300 |
Why?
| | Cholesterol, LDL | 5 | 2018 | 360 | 0.300 |
Why?
| | Preventive Health Services | 1 | 2011 | 153 | 0.300 |
Why?
| | Weight Loss | 6 | 2026 | 859 | 0.290 |
Why?
| | Delivery of Health Care | 1 | 2016 | 947 | 0.290 |
Why?
| | Diabetic Ketoacidosis | 2 | 2022 | 210 | 0.290 |
Why?
| | Transgender Persons | 2 | 2024 | 210 | 0.290 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 668 | 0.280 |
Why?
| | Hypolipidemic Agents | 3 | 2020 | 89 | 0.270 |
Why?
| | Energy Metabolism | 3 | 2024 | 935 | 0.270 |
Why?
| | Bone Density | 2 | 2025 | 487 | 0.270 |
Why?
| | Disease Progression | 8 | 2022 | 2865 | 0.270 |
Why?
| | Melatonin | 4 | 2025 | 163 | 0.260 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2023 | 701 | 0.260 |
Why?
| | Predictive Value of Tests | 6 | 2024 | 2123 | 0.250 |
Why?
| | Cholesterol, HDL | 6 | 2021 | 201 | 0.250 |
Why?
| | Time Factors | 10 | 2026 | 7133 | 0.250 |
Why?
| | Linear Models | 4 | 2019 | 849 | 0.250 |
Why?
| | Reproducibility of Results | 5 | 2021 | 3416 | 0.250 |
Why?
| | Sleep Initiation and Maintenance Disorders | 2 | 2020 | 196 | 0.240 |
Why?
| | Minority Groups | 2 | 2020 | 285 | 0.240 |
Why?
| | Oxygen | 3 | 2024 | 981 | 0.240 |
Why?
| | Peptide YY | 1 | 2026 | 28 | 0.240 |
Why?
| | Cardio-Renal Syndrome | 1 | 2026 | 20 | 0.240 |
Why?
| | Longitudinal Studies | 8 | 2026 | 2967 | 0.240 |
Why?
| | Food Deprivation | 1 | 2006 | 28 | 0.230 |
Why?
| | Bromocriptine | 2 | 2022 | 31 | 0.230 |
Why?
| | Janus Kinases | 1 | 2026 | 21 | 0.230 |
Why?
| | STAT Transcription Factors | 1 | 2026 | 25 | 0.230 |
Why?
| | Health Status | 1 | 2011 | 835 | 0.230 |
Why?
| | Colorado | 9 | 2020 | 4556 | 0.230 |
Why?
| | Diastole | 3 | 2022 | 146 | 0.230 |
Why?
| | Hypothalamus | 1 | 2026 | 163 | 0.220 |
Why?
| | Body Fat Distribution | 2 | 2019 | 46 | 0.220 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2026 | 138 | 0.220 |
Why?
| | Early Medical Intervention | 2 | 2018 | 63 | 0.220 |
Why?
| | Age Factors | 8 | 2021 | 3346 | 0.220 |
Why?
| | Reproductive Health | 2 | 2023 | 91 | 0.220 |
Why?
| | Blood Pressure | 6 | 2019 | 1782 | 0.210 |
Why?
| | Biological Clocks | 1 | 2025 | 48 | 0.210 |
Why?
| | Cystatin C | 2 | 2014 | 66 | 0.210 |
Why?
| | 3T3-L1 Cells | 1 | 2004 | 36 | 0.210 |
Why?
| | Accelerometry | 2 | 2026 | 119 | 0.210 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2004 | 37 | 0.210 |
Why?
| | United States | 11 | 2021 | 16123 | 0.200 |
Why?
| | Gastrointestinal Microbiome | 3 | 2021 | 768 | 0.200 |
Why?
| | Risk Assessment | 5 | 2022 | 3752 | 0.200 |
Why?
| | Body Weight | 4 | 2020 | 972 | 0.200 |
Why?
| | Physical Conditioning, Animal | 1 | 2006 | 242 | 0.200 |
Why?
| | Oral Health | 2 | 2015 | 139 | 0.190 |
Why?
| | Calorimetry, Indirect | 2 | 2024 | 72 | 0.190 |
Why?
| | Muscles | 1 | 2004 | 330 | 0.190 |
Why?
| | Middle Aged | 14 | 2024 | 36302 | 0.190 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 217 | 0.190 |
Why?
| | Aging | 1 | 2014 | 1973 | 0.190 |
Why?
| | Hepatitis | 1 | 2003 | 43 | 0.190 |
Why?
| | Hyperoxia | 1 | 2024 | 107 | 0.180 |
Why?
| | Quality of Life | 2 | 2014 | 3210 | 0.180 |
Why?
| | Adipocytes | 1 | 2004 | 223 | 0.180 |
Why?
| | Systole | 2 | 2020 | 181 | 0.180 |
Why?
| | Gastroplasty | 1 | 2022 | 32 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2023 | 1751 | 0.180 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2019 | 52 | 0.180 |
Why?
| | Mucous Membrane | 1 | 2023 | 128 | 0.180 |
Why?
| | Waist Circumference | 4 | 2020 | 143 | 0.180 |
Why?
| | Mother-Child Relations | 1 | 2023 | 131 | 0.180 |
Why?
| | Self Report | 2 | 2024 | 876 | 0.170 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2018 | 75 | 0.170 |
Why?
| | Disease Management | 2 | 2016 | 653 | 0.170 |
Why?
| | Healthy Volunteers | 1 | 2022 | 219 | 0.170 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2933 | 0.160 |
Why?
| | Eating | 2 | 2021 | 387 | 0.160 |
Why?
| | Lipoproteins, HDL | 2 | 2021 | 100 | 0.160 |
Why?
| | Kidney Tubules | 1 | 2021 | 118 | 0.160 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2024 | 235 | 0.160 |
Why?
| | CD40 Ligand | 1 | 2000 | 40 | 0.160 |
Why?
| | Pregnancy | 6 | 2023 | 7215 | 0.160 |
Why?
| | Adolescent Behavior | 2 | 2017 | 497 | 0.160 |
Why?
| | Exercise Test | 2 | 2016 | 630 | 0.150 |
Why?
| | Renal Insufficiency | 1 | 2022 | 172 | 0.150 |
Why?
| | Factor VIII | 1 | 2000 | 106 | 0.150 |
Why?
| | Risk | 3 | 2017 | 923 | 0.150 |
Why?
| | Glucagon-Secreting Cells | 1 | 2020 | 25 | 0.150 |
Why?
| | Dental Caries | 1 | 2021 | 173 | 0.150 |
Why?
| | Glycerol | 2 | 2019 | 90 | 0.150 |
Why?
| | Weight Gain | 2 | 2021 | 561 | 0.150 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 782 | 0.150 |
Why?
| | Drug Therapy, Combination | 2 | 2019 | 1043 | 0.150 |
Why?
| | Klinefelter Syndrome | 1 | 2020 | 69 | 0.140 |
Why?
| | Physicians, Women | 1 | 2020 | 90 | 0.140 |
Why?
| | Precision Medicine | 3 | 2023 | 461 | 0.140 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2019 | 52 | 0.140 |
Why?
| | Gluconeogenesis | 1 | 2019 | 81 | 0.140 |
Why?
| | Subcutaneous Fat | 1 | 2019 | 79 | 0.140 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2020 | 214 | 0.140 |
Why?
| | Estradiol | 2 | 2019 | 515 | 0.140 |
Why?
| | Carnitine | 1 | 2019 | 91 | 0.140 |
Why?
| | Depression | 4 | 2025 | 1557 | 0.140 |
Why?
| | Gonadal Steroid Hormones | 1 | 2019 | 143 | 0.140 |
Why?
| | Exercise Therapy | 3 | 2019 | 475 | 0.140 |
Why?
| | Career Choice | 1 | 2020 | 235 | 0.130 |
Why?
| | Peer Group | 1 | 2020 | 256 | 0.130 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 48 | 0.130 |
Why?
| | Sugars | 1 | 2018 | 40 | 0.130 |
Why?
| | Universities | 1 | 2020 | 445 | 0.130 |
Why?
| | Glucagon | 2 | 2023 | 114 | 0.130 |
Why?
| | Aminopyridines | 1 | 2018 | 129 | 0.130 |
Why?
| | Biodiversity | 1 | 2020 | 311 | 0.130 |
Why?
| | T-Lymphocytes | 3 | 2021 | 1997 | 0.130 |
Why?
| | Saliva | 3 | 2025 | 249 | 0.130 |
Why?
| | Socioeconomic Factors | 3 | 2016 | 1327 | 0.130 |
Why?
| | Retrospective Studies | 10 | 2023 | 17325 | 0.130 |
Why?
| | Social Media | 1 | 2020 | 167 | 0.130 |
Why?
| | Fructose | 1 | 2018 | 132 | 0.130 |
Why?
| | Depressive Disorder | 1 | 2020 | 374 | 0.130 |
Why?
| | Adenosine Diphosphate | 1 | 2017 | 83 | 0.130 |
Why?
| | Peptides | 1 | 2023 | 998 | 0.130 |
Why?
| | Autoimmunity | 2 | 2021 | 933 | 0.130 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1482 | 0.120 |
Why?
| | Magnetic Resonance Angiography | 1 | 2018 | 251 | 0.120 |
Why?
| | Benzodioxoles | 1 | 2018 | 161 | 0.120 |
Why?
| | Allostasis | 1 | 2016 | 17 | 0.120 |
Why?
| | Occupational Exposure | 1 | 2020 | 355 | 0.120 |
Why?
| | Diet Therapy | 1 | 2016 | 36 | 0.120 |
Why?
| | Nutrition Surveys | 1 | 2017 | 279 | 0.120 |
Why?
| | Dyslipidemias | 1 | 2018 | 184 | 0.120 |
Why?
| | Monitoring, Ambulatory | 1 | 2016 | 89 | 0.120 |
Why?
| | Acute Kidney Injury | 2 | 2021 | 874 | 0.120 |
Why?
| | Area Under Curve | 1 | 2016 | 332 | 0.120 |
Why?
| | Quinolones | 1 | 2018 | 204 | 0.120 |
Why?
| | Transcription Factors | 1 | 2004 | 1736 | 0.120 |
Why?
| | Societies, Medical | 1 | 2020 | 900 | 0.120 |
Why?
| | Social Support | 1 | 2020 | 651 | 0.120 |
Why?
| | Aminophenols | 1 | 2018 | 203 | 0.120 |
Why?
| | Echocardiography, Doppler | 1 | 2016 | 115 | 0.110 |
Why?
| | Muscle Strength | 2 | 2017 | 332 | 0.110 |
Why?
| | Metabolome | 1 | 2019 | 391 | 0.110 |
Why?
| | Pandemics | 2 | 2022 | 1711 | 0.110 |
Why?
| | Androgens | 1 | 2016 | 181 | 0.110 |
Why?
| | Signal Transduction | 2 | 2026 | 5223 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 391 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 384 | 0.110 |
Why?
| | Algorithms | 3 | 2021 | 1850 | 0.110 |
Why?
| | Research Design | 2 | 2019 | 1139 | 0.110 |
Why?
| | Bacteria | 1 | 2020 | 766 | 0.100 |
Why?
| | Regional Blood Flow | 1 | 2016 | 514 | 0.100 |
Why?
| | Phosphorus | 1 | 2014 | 90 | 0.100 |
Why?
| | Child, Preschool | 7 | 2021 | 11868 | 0.100 |
Why?
| | Child Health | 1 | 2015 | 154 | 0.100 |
Why?
| | Stress, Mechanical | 1 | 2016 | 494 | 0.100 |
Why?
| | Pregnancy in Diabetics | 1 | 2015 | 123 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2018 | 584 | 0.100 |
Why?
| | Autoantibodies | 1 | 2021 | 1509 | 0.100 |
Why?
| | Mitochondria | 2 | 2024 | 992 | 0.100 |
Why?
| | Health Status Disparities | 1 | 2016 | 321 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2000 | 1505 | 0.100 |
Why?
| | Health Literacy | 1 | 2015 | 186 | 0.100 |
Why?
| | Metabolomics | 1 | 2019 | 733 | 0.100 |
Why?
| | American Heart Association | 1 | 2014 | 358 | 0.090 |
Why?
| | Hypoxia | 1 | 2020 | 1199 | 0.090 |
Why?
| | Chitinase-3-Like Protein 1 | 2 | 2022 | 18 | 0.090 |
Why?
| | Drug Combinations | 3 | 2019 | 396 | 0.090 |
Why?
| | Animals | 10 | 2018 | 38097 | 0.090 |
Why?
| | Adolescent Health Services | 1 | 2013 | 74 | 0.090 |
Why?
| | Blotting, Western | 2 | 2006 | 1184 | 0.090 |
Why?
| | Rats | 6 | 2011 | 5585 | 0.090 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 860 | 0.090 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 180 | 0.090 |
Why?
| | Pregnancy Outcome | 1 | 2015 | 504 | 0.090 |
Why?
| | Histidine | 2 | 2022 | 66 | 0.090 |
Why?
| | Muscle Cells | 1 | 2012 | 41 | 0.090 |
Why?
| | Medication Adherence | 1 | 2016 | 540 | 0.090 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 6085 | 0.090 |
Why?
| | Muscle Contraction | 1 | 2014 | 429 | 0.090 |
Why?
| | Health Behavior | 1 | 2017 | 791 | 0.090 |
Why?
| | Self Care | 1 | 2014 | 392 | 0.080 |
Why?
| | Physicians | 1 | 2020 | 956 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2016 | 756 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1547 | 0.080 |
Why?
| | Matrix Metalloproteinases | 1 | 2011 | 95 | 0.080 |
Why?
| | Plaque, Atherosclerotic | 1 | 2011 | 61 | 0.080 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 740 | 0.080 |
Why?
| | Hypertension | 1 | 2019 | 1276 | 0.080 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 199 | 0.080 |
Why?
| | Models, Biological | 1 | 2017 | 1764 | 0.080 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 287 | 0.080 |
Why?
| | Phenotype | 2 | 2022 | 3170 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1582 | 0.070 |
Why?
| | Treatment Failure | 2 | 2023 | 360 | 0.070 |
Why?
| | Plethysmography | 1 | 2009 | 104 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2014 | 777 | 0.070 |
Why?
| | Calcinosis | 1 | 2011 | 234 | 0.070 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2009 | 124 | 0.070 |
Why?
| | Aspartate Aminotransferases | 1 | 2008 | 85 | 0.070 |
Why?
| | Oxidation-Reduction | 2 | 2024 | 1068 | 0.070 |
Why?
| | Rats, Zucker | 1 | 2007 | 32 | 0.070 |
Why?
| | Blood Flow Velocity | 1 | 2009 | 421 | 0.070 |
Why?
| | Infant | 4 | 2021 | 10090 | 0.070 |
Why?
| | PPAR alpha | 1 | 2007 | 55 | 0.060 |
Why?
| | Fenofibrate | 1 | 2007 | 28 | 0.060 |
Why?
| | Ultrasonography | 2 | 2008 | 788 | 0.060 |
Why?
| | Thiazoles | 2 | 2019 | 142 | 0.060 |
Why?
| | Atherosclerosis | 1 | 2011 | 409 | 0.060 |
Why?
| | Forced Expiratory Volume | 2 | 2018 | 450 | 0.060 |
Why?
| | C-Reactive Protein | 1 | 2009 | 423 | 0.060 |
Why?
| | Primary Health Care | 2 | 2018 | 1737 | 0.060 |
Why?
| | Parents | 1 | 2015 | 1407 | 0.060 |
Why?
| | Incidence | 3 | 2021 | 2933 | 0.060 |
Why?
| | Thiazolidinediones | 1 | 2007 | 143 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2015 | 6464 | 0.060 |
Why?
| | Interleukin-6 | 2 | 2009 | 779 | 0.060 |
Why?
| | Random Allocation | 2 | 2021 | 365 | 0.060 |
Why?
| | Fatty Acid Synthases | 1 | 2006 | 23 | 0.060 |
Why?
| | Hyperlipidemias | 1 | 2007 | 120 | 0.060 |
Why?
| | Immunoconjugates | 2 | 1998 | 138 | 0.060 |
Why?
| | Adipokines | 1 | 2026 | 57 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2026 | 318 | 0.060 |
Why?
| | Macaca mulatta | 1 | 2006 | 186 | 0.060 |
Why?
| | Urban Population | 1 | 2008 | 494 | 0.060 |
Why?
| | Heart Rate | 1 | 2009 | 856 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 444 | 0.050 |
Why?
| | Aged | 6 | 2022 | 26215 | 0.050 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 58 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2011 | 2525 | 0.050 |
Why?
| | Motor Activity | 1 | 2009 | 718 | 0.050 |
Why?
| | Hospitals, Pediatric | 2 | 2019 | 558 | 0.050 |
Why?
| | Chromones | 1 | 2004 | 43 | 0.050 |
Why?
| | Coronary Artery Disease | 1 | 2011 | 750 | 0.050 |
Why?
| | Polysomnography | 1 | 2025 | 239 | 0.050 |
Why?
| | Androstadienes | 1 | 2004 | 77 | 0.050 |
Why?
| | Patient Selection | 1 | 2008 | 739 | 0.050 |
Why?
| | Basal Metabolism | 1 | 2024 | 59 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1270 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2021 | 2000 | 0.050 |
Why?
| | Graft Rejection | 2 | 1998 | 521 | 0.050 |
Why?
| | Flavonoids | 1 | 2004 | 85 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 979 | 0.050 |
Why?
| | Morpholines | 1 | 2004 | 130 | 0.050 |
Why?
| | Cholesterol | 1 | 2005 | 408 | 0.050 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 92 | 0.050 |
Why?
| | Nuclear Family | 1 | 2023 | 50 | 0.050 |
Why?
| | Cysts | 1 | 2024 | 112 | 0.050 |
Why?
| | Inflammation | 2 | 2018 | 2883 | 0.050 |
Why?
| | Malates | 1 | 2022 | 8 | 0.050 |
Why?
| | Fumarates | 1 | 2022 | 10 | 0.050 |
Why?
| | Regression Analysis | 1 | 2025 | 1001 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 1512 | 0.050 |
Why?
| | Threonine | 1 | 2022 | 44 | 0.050 |
Why?
| | Glycolysis | 1 | 2024 | 340 | 0.050 |
Why?
| | Awareness | 1 | 2023 | 110 | 0.050 |
Why?
| | MAP Kinase Signaling System | 1 | 2004 | 308 | 0.040 |
Why?
| | Carboxylic Acids | 1 | 2022 | 31 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 383 | 0.040 |
Why?
| | Light | 1 | 2025 | 403 | 0.040 |
Why?
| | Off-Label Use | 1 | 2022 | 51 | 0.040 |
Why?
| | Glycoproteins | 1 | 2024 | 354 | 0.040 |
Why?
| | Phenylalanine | 1 | 2022 | 69 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2022 | 112 | 0.040 |
Why?
| | Lipocalin-2 | 1 | 2022 | 80 | 0.040 |
Why?
| | Leucine | 1 | 2022 | 116 | 0.040 |
Why?
| | Albumins | 1 | 2022 | 119 | 0.040 |
Why?
| | Bacteroidetes | 1 | 2021 | 21 | 0.040 |
Why?
| | Liraglutide | 1 | 2021 | 32 | 0.040 |
Why?
| | Glycine | 1 | 2022 | 186 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2023 | 1420 | 0.040 |
Why?
| | Longevity | 1 | 2022 | 178 | 0.040 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2021 | 88 | 0.040 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 5 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 286 | 0.040 |
Why?
| | Tryptophan | 1 | 2022 | 182 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 821 | 0.040 |
Why?
| | Interleukin-18 | 1 | 2022 | 234 | 0.040 |
Why?
| | Iohexol | 1 | 2020 | 23 | 0.040 |
Why?
| | Insulin Glargine | 1 | 2021 | 88 | 0.040 |
Why?
| | Furosemide | 1 | 2020 | 37 | 0.040 |
Why?
| | Isoantibodies | 1 | 2000 | 57 | 0.040 |
Why?
| | Wrist | 1 | 2021 | 60 | 0.040 |
Why?
| | Mutation | 2 | 2018 | 4090 | 0.040 |
Why?
| | Antigens, Differentiation | 2 | 1998 | 76 | 0.040 |
Why?
| | Counseling | 1 | 2023 | 401 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 2028 | 0.040 |
Why?
| | Canada | 1 | 2021 | 432 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2006 | 2805 | 0.040 |
Why?
| | Sexual Maturation | 1 | 2019 | 48 | 0.040 |
Why?
| | Jet Lag Syndrome | 1 | 2019 | 13 | 0.040 |
Why?
| | Research | 1 | 2022 | 431 | 0.040 |
Why?
| | Hyperuricemia | 1 | 2019 | 47 | 0.040 |
Why?
| | Reference Values | 1 | 2020 | 798 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2000 | 280 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2019 | 156 | 0.040 |
Why?
| | Carbon Isotopes | 1 | 2019 | 143 | 0.040 |
Why?
| | Cell Line | 1 | 2004 | 2823 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 508 | 0.030 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 30 | 0.030 |
Why?
| | Hemophilia A | 1 | 2000 | 148 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 43 | 0.030 |
Why?
| | High Fructose Corn Syrup | 1 | 2018 | 9 | 0.030 |
Why?
| | Autoantigens | 1 | 2021 | 427 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 533 | 0.030 |
Why?
| | Neoplasms | 1 | 2014 | 2913 | 0.030 |
Why?
| | Carbonated Beverages | 1 | 2018 | 16 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 1998 | 31 | 0.030 |
Why?
| | Homozygote | 1 | 2018 | 199 | 0.030 |
Why?
| | Genetic Variation | 1 | 2023 | 976 | 0.030 |
Why?
| | Cell Respiration | 1 | 2018 | 105 | 0.030 |
Why?
| | Wakefulness | 1 | 2019 | 170 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 168 | 0.030 |
Why?
| | Psychotherapy, Group | 1 | 2018 | 79 | 0.030 |
Why?
| | Fructokinases | 1 | 2018 | 42 | 0.030 |
Why?
| | RNA | 1 | 2004 | 912 | 0.030 |
Why?
| | Bone Diseases, Metabolic | 1 | 2018 | 58 | 0.030 |
Why?
| | Anxiety | 1 | 2025 | 1122 | 0.030 |
Why?
| | Feces | 1 | 2021 | 496 | 0.030 |
Why?
| | Beverages | 1 | 2018 | 68 | 0.030 |
Why?
| | Phosphorus Isotopes | 1 | 2017 | 8 | 0.030 |
Why?
| | Vital Capacity | 1 | 2018 | 292 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2023 | 675 | 0.030 |
Why?
| | Mothers | 1 | 2023 | 765 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2019 | 1300 | 0.030 |
Why?
| | Morbidity | 1 | 2017 | 322 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 532 | 0.030 |
Why?
| | Communication | 1 | 2023 | 977 | 0.030 |
Why?
| | Postprandial Period | 1 | 2017 | 114 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2018 | 298 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 1115 | 0.030 |
Why?
| | Proteome | 1 | 2021 | 513 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2019 | 554 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 428 | 0.030 |
Why?
| | Physicians, Primary Care | 1 | 2018 | 208 | 0.030 |
Why?
| | Arginine | 1 | 2017 | 264 | 0.030 |
Why?
| | Anti-Infective Agents | 1 | 1998 | 232 | 0.030 |
Why?
| | Deuterium | 1 | 2015 | 101 | 0.030 |
Why?
| | Stillbirth | 1 | 2015 | 82 | 0.030 |
Why?
| | Insurance, Dental | 1 | 2014 | 11 | 0.030 |
Why?
| | Dental Care for Children | 1 | 2014 | 12 | 0.030 |
Why?
| | International Agencies | 1 | 2014 | 30 | 0.030 |
Why?
| | Delivery, Obstetric | 1 | 2015 | 160 | 0.030 |
Why?
| | Adolescent Medicine | 1 | 2014 | 26 | 0.030 |
Why?
| | Societies, Scientific | 1 | 2014 | 50 | 0.030 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2018 | 373 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 1998 | 1133 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 303 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 507 | 0.030 |
Why?
| | Rats, Inbred Lew | 3 | 1998 | 105 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 222 | 0.020 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 146 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 203 | 0.020 |
Why?
| | Prenatal Care | 1 | 2015 | 309 | 0.020 |
Why?
| | Observer Variation | 1 | 2014 | 357 | 0.020 |
Why?
| | Rats, Inbred F344 | 3 | 1998 | 268 | 0.020 |
Why?
| | Fractures, Bone | 1 | 2018 | 428 | 0.020 |
Why?
| | Survival Rate | 1 | 2017 | 2094 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2018 | 692 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2015 | 560 | 0.020 |
Why?
| | Intracellular Space | 1 | 2012 | 64 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 1996 | 838 | 0.020 |
Why?
| | DNA | 1 | 2018 | 1437 | 0.020 |
Why?
| | Mice | 2 | 2011 | 18355 | 0.020 |
Why?
| | Patient Compliance | 1 | 2015 | 588 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 672 | 0.020 |
Why?
| | Self Concept | 1 | 2013 | 254 | 0.020 |
Why?
| | Registries | 1 | 2020 | 2410 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 1996 | 712 | 0.020 |
Why?
| | Insulin Infusion Systems | 1 | 2015 | 480 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 560 | 0.020 |
Why?
| | Family | 1 | 2014 | 685 | 0.020 |
Why?
| | Diet | 1 | 2017 | 1278 | 0.020 |
Why?
| | Apoptosis | 1 | 1998 | 2443 | 0.020 |
Why?
| | Psychometrics | 1 | 2013 | 731 | 0.020 |
Why?
| | Abatacept | 2 | 1998 | 56 | 0.020 |
Why?
| | CTLA-4 Antigen | 2 | 1998 | 105 | 0.020 |
Why?
| | Proteinuria | 2 | 1997 | 104 | 0.020 |
Why?
| | Cyclosporine | 2 | 1998 | 256 | 0.010 |
Why?
| | Caregivers | 1 | 2014 | 1074 | 0.010 |
Why?
| | Antigens, CD | 2 | 1998 | 558 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 8346 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 5992 | 0.010 |
Why?
| | Trazodone | 1 | 1998 | 2 | 0.010 |
Why?
| | CD28 Antigens | 1 | 1998 | 59 | 0.010 |
Why?
| | B7-1 Antigen | 1 | 1998 | 55 | 0.010 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 1998 | 46 | 0.010 |
Why?
| | Endothelins | 1 | 1997 | 61 | 0.010 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 1997 | 41 | 0.010 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 132 | 0.010 |
Why?
| | Isoantigens | 1 | 1996 | 17 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 1998 | 419 | 0.010 |
Why?
| | Organ Size | 1 | 1997 | 461 | 0.010 |
Why?
| | Nephrectomy | 1 | 1997 | 163 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1998 | 1043 | 0.010 |
Why?
| | Biopsy | 1 | 1998 | 1082 | 0.010 |
Why?
| | Reperfusion Injury | 1 | 1997 | 292 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1997 | 784 | 0.010 |
Why?
| | Interleukin-1 | 1 | 1997 | 961 | 0.010 |
Why?
| | Drug Overdose | 1 | 1998 | 375 | 0.010 |
Why?
| | Kidney Diseases | 1 | 1997 | 426 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 1997 | 1723 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1997 | 1217 | 0.010 |
Why?
| | Chronic Disease | 1 | 1997 | 1812 | 0.010 |
Why?
| | Macrophages | 1 | 1996 | 1507 | 0.000 |
Why?
| | Disease Models, Animal | 1 | 1996 | 4568 | 0.000 |
Why?
|
|
Nadeau's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|